Shipments of oxymorphone hydrochloride extended release (Opana ER) will end on September 1, Endo International announced Friday. According to a company spokeswoman, shipments will continue through that date to "enable time for patients currently taking Opana ER to work with their physicians to convert to an appropriate alternative treatment." She said the company's third-party manufacturer ended production of the drug in connection with Endo's recent announcement that it would pull the drug from store shelves. The spokeswoman stressed, "It is important to note that there is no recall." FDA last month asked Endo to stop selling the drug. The agency linked a 2012 reformulation of the drug to injection drug use and a 2015 outbreak of HIV and hepatitis C in Indiana. Also on Friday, Endo said that it will close plants in Huntsville, AL, where it makes generic opioids and eliminate 875 jobs.